"Moderna Inc. has begun dosing patients in a mid-to-late stage study of its COVID-19 vaccine, mRNA-1273, in children aged six months to less than 12 years, the company said on Tuesday."
"The study will assess the safety and effectiveness of two doses of mRNA-1273 given 28 days apart, and intends to enrol about 6,750 children in Canada and the United States."
"The study will assess the safety and effectiveness of two doses of mRNA-1273 given 28 days apart, and intends to enrol about 6,750 children in Canada and the United States."